Source - RNS
RNS Number : 2364J
Synairgen plc
08 September 2016


8 September 2016



("Synairgen" or "the Company")


Notice of Interim Results


Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its interim results for the six-month period ended 30 June 2016 on 22 September 2016.





For further information, please contact:


Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800



Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500


Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Sue Stuart / Laura Thornton

[email protected]

Tel: +44 (0) 20 3709 5701



Notes for Editors


About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions. This approach has been validated by the licensing agreement formed with AstraZeneca in June 2014 for Synairgen's SNG001 (AZD9412) programme in asthma/COPD. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see 

This information is provided by RNS
The company news service from the London Stock Exchange

Related Charts

Synairgen (SNG)

-1.25p (-6.58%)
delayed 16:55PM